Who are Actigall's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Avandia, Lasix, Furadantin, Frusemide, MACRODANTIN, Actos.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ursodiol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Actigall — Competitive Intelligence Brief

Actigall (URSODIOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile Acid [EPC]. Area: Immunology.

marketed Bile Acid [EPC] CDGSH iron-sulfur domain-containing protein 1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Actigall (URSODIOL) — AbbVie.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Actigall TARGET	URSODIOL	AbbVie	marketed	Bile Acid [EPC]	CDGSH iron-sulfur domain-containing protein 1	1987-01-01
Avandia	ROSIGLITAZONE	Woodward	marketed	Peroxisome Proliferator Receptor gamma Agonist	CDGSH iron-sulfur domain-containing protein 1	1999-01-01
Lasix	furosemide	Generic (originally Hoechst AG)	marketed	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
Furadantin	NITROFURANTOIN		marketed	Nitrofuran Antibacterial [EPC]	CDGSH iron-sulfur domain-containing protein 1	1953-01-01
Frusemide	Frusemide	Melbourne Health	marketed		ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35
MACRODANTIN	NITROFURANTOIN, MACROCRYSTALLINE	ALMATICA	marketed	Nitrofuran Antibacterial [EPC]	Mitochondrial pyruvate carrier 2, CDGSH iron-sulfur domain-containing protein 1, Glucose-6-phosphate 1-dehydrogenase
Actos	pioglitazone	Takeda	marketed		CDGSH iron-sulfur domain-containing protein 2, Bile salt export pump, CDGSH iron-sulfur domain-containing protein 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-04-03 — Lasix · 11433044 · Method of Use · US
2034-04-03 — Lasix · 9884039 · Method of Use · US
2034-04-03 — Lasix · 12370168 · Formulation · US
2034-04-03 — Lasix · 10272064 · Formulation · US

Sponsor landscape (Bile Acid [EPC] class)

· 1 drug in this class
AbbVie · 1 drug in this class
Mirum · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actigall — Competitive Intelligence Brief. https://druglandscape.com/ci/ursodiol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab